REDWOOD CITY, Calif., May 4 /PRNewswire-FirstCall/ -- FoxHollow
Technologies, Inc. (NASDAQ:FOXH), which manufactures and markets
the SilverHawk(TM) Plaque Excision System -- a minimally invasive
device for the treatment of peripheral artery disease (PAD) --
today reported results for the first quarter of fiscal 2006. For
the quarter ended March 31, 2006, the company had revenues of $46.6
million, a 117 percent increase over revenues of $21.5 million in
the same period a year ago, and an 11 percent increase over
revenues of $41.9 million in the fourth quarter of 2005. Revenues
for the first quarter of 2006 include $2.1 million from the
company's collaboration with Merck & Co., Inc., which was
signed in September of 2005. FoxHollow reported a gross margin on
product sales of 75 percent versus 59 percent in the first quarter
of 2005 and 70 percent in the fourth quarter of 2005. The net loss
for the first quarter of 2006 was $14.6 million, or $0.60 per
share, compared to a net loss of $6.5 million, or $0.29 per share,
in the same period a year ago and a net loss of $160,000, or $0.01
per share, in the fourth quarter of 2005. Included in these results
are non-cash stock- based compensation expenses of $14.8 million in
the first quarter of 2006, $1.8 million in the first quarter of
2005 and $1.2 million in the fourth quarter of 2005. Stock-based
compensation charges for the first quarter of 2006 include $2.5
million related to the adoption of FAS123 (R) and a one-time charge
of $11.4 million related to the retirement of the company's former
chief executive officer. Net income, excluding stock-based
compensation expense, in the first quarter of 2006 was $155,000, or
$0.01 per diluted share. Net income excluding stock-based
compensation expense is a non-GAAP financial measure. This measure
provides an indication of FoxHollow's performance before certain
charges that are considered by management to be outside of the
company's core operating results. In addition, net income excluding
stock-based compensation expense is among the primary indicators
FoxHollow's management uses as a basis for planning and forecasting
of future periods. The presentation of this additional information
should not be considered in isolation or as a substitute for net
income prepared in accordance with generally accepted accounting
principles. "We believe these record quarterly revenues demonstrate
that the company is continuing to make meaningful progress in the
realization of its vision to treat a growing number of patients
suffering from PAD with the SilverHawk, and that the patient
outcomes and our market education strategies are resonating with
the clinical community," said Dr. John Simpson, interim chief
executive officer. "Our performance speaks to the increasing
productivity of FoxHollow's sales force in driving greater
penetration of existing accounts, adding new centers and generating
increasing physician referral activity," he added. "We are hitting
key milestones in our product development efforts and expect to
introduce four new versions of the SilverHawk during the current
year. This week we also signed an agreement with Cook Inc. to
distribute a line of introducer sheaths commonly used during the
SilverHawk procedure. This is the first agreement in our ongoing
effort to leverage our sales and marketing infrastructure through
the expansion of our product portfolio," Dr. Simpson continued.
With respect to the company's Merck collaboration, Dr. Simpson
commented, "For the initial six-months of the agreement, all
scientific and commercial objectives have been met or exceeded. In
particular, we have completed a research effort demonstrating that
plaque excised by the SilverHawk can be subjected to microarray
analysis of gene expression and that biologically relevant gene
expression signatures can be identified. Merck and we are now in
the process of launching additional research efforts to identify
novel biomarkers and drug targets for the treatment of
atherosclerosis." Guidance for the Second Quarter and Fiscal Year
2006 FoxHollow expects revenues of $46-$48 million for the second
quarter of 2006, including approximately $200,000 of research
collaboration revenue related to the Merck relationship. Research
collaboration revenue will decrease in the second quarter and then
increase in the second half of the year, as more significant
numbers of patients are enrolled in the two new studies. The
company expects a net loss per share of $0.12-$0.16 for the second
quarter. This includes stock-based compensation expense of
approximately $3.6 million. Diluted earnings (loss) per share,
excluding stock-based compensation expense, are expected to be in
the range of $(0.02)- $0.02. For the full year 2006, the company
reiterated prior revenue guidance of $210-$220 million, including
$8-$10 million from the Merck collaboration. The company is
expecting a net loss per share of $0.20-$0.40 per share, and
diluted earnings per share, excluding stock-based compensation
expense, in the range of $0.60-$0.80. The company noted that
stock-based compensation expense for both the second quarter and
full year 2006 could vary significantly, depending on the price of
the company's stock and future stock grant practices, as well as
other factors. Conference Call The company will hold a conference
call today at 2 p.m. Pacific Time (5 p.m. Eastern Time). The
teleconference can be accessed via the investor relations section
of the company's website at http://www.foxhollowtech.com/, or by
calling 888-889-5602 (domestic) or 973-582-2734 (international).
Please dial in or access the website 10-15 minutes prior to the
beginning of the call. A replay of the conference call will be
available four hours after the conference call concludes through 12
a.m. Eastern Time, May 18, 2006, by dialing 877-519-4471, or
973-341-3080, passcode 7315176. An online archive of the webcast
will be available for a minimum of two months by accessing the
investor relations portion of the company's website at
http://www.foxhollowtech.com/. About FoxHollow Technologies
FoxHollow Technologies, Inc., develops and markets minimally
invasive plaque excision devices for the treatment of peripheral
artery disease (PAD). An estimated 12 million people in the U.S.
are thought to suffer from PAD, with 2.5 million patients currently
diagnosed. PAD results from plaque that accumulates in the arteries
and blocks blood flow in the legs. These blockages can result in
severe pain for patients and very limited physical mobility. The
company's SilverHawk System is a minimally invasive method of
removing the obstructive plaque and restoring blood flow to the
legs and feet. For more information, please visit our website at
http://www.foxhollowtech.com/. This press release contains
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Statements in this press
release regarding FoxHollow's business that are not historical
facts may be "forward-looking statements" that involve risks and
uncertainties. Specifically, statements regarding the company's
financial guidance for the second quarter and full year 2006,
future revenue from the Merck collaboration and expectations
regarding future SilverHawk product releases are forward-looking
statements involving risks and uncertainties. FoxHollow's first
quarter 2006 financial results, as discussed in this release, are
preliminary and unaudited, and subject to adjustment. Forward-
looking statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties, which may
cause FoxHollow's actual results to differ materially from the
statements contained herein. The potential risks and uncertainties
that could cause actual results to differ from the results
predicted are included under the caption, "Factors Affecting Future
Operating Results," in "Management's Discussion and Analysis of
Financial Condition and Results of Operations," in our report on
Form 10-K for the year ended December 31, 2005, which is on file
with the SEC and available on our investor relations website at
http://investor.foxhollowtech.com/ and on the SEC's website at
http://www.sec.gov/. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they
are made. FoxHollow undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date they were made, or to reflect the
occurrence of unanticipated events. Contacts: Matt Ferguson Chief
Financial Officer 650-421-8501 Jonathan Menachem Investor Relations
650-421-8449 Robin Gaffney Media Relations 650-421-8614 FOXHOLLOW
TECHNOLOGIES, INC. CONDENSED BALANCE SHEETS (in thousands)
(unaudited) March 31, December 31, 2006 2005 ----------
------------- Assets Current assets: Cash and cash equivalents
$24,048 $24,249 Short-term investments 35,319 35,666 Accounts
receivable, net 23,759 21,831 Inventories 14,752 15,607 Prepaid
expenses and other current assets 1,890 1,846 ----------
------------- Total current assets 99,768 99,199 Property and
equipment, net 8,439 8,442 Other assets 565 564 ----------
------------- Total assets $108,772 $108,205 ==========
============= Liabilities and Stockholders' Equity Current
liabilities: Accounts payable $6,140 $7,072 Accrued liabilities
13,587 11,163 Deferred revenue 4,142 6,206 ---------- -------------
Total liabilities 23,869 24,441 ========== =============
Stockholders' equity: Common stock 25 24 Additional paid-in capital
189,073 178,011 Deferred stock-based compensation (4,383) (9,066)
Other comprehensive loss (68) (99) Accumulated deficit (99,744)
(85,106) ---------- ------------- Total stockholders' equity 84,903
83,764 ---------- ------------- Total liabilities and stockholders'
equity $108,772 $108,205 ========== ============= FOXHOLLOW
TECHNOLOGIES, INC. CONDENSED STATEMENTS OF OPERATIONS (in
thousands, except per share amounts) (unaudited) Three Months Ended
March 31, ----------------------------- 2006 2005 ---------
--------- Revenue: Product $44,583 $21,478 Research collaboration
2,064 -- --------- --------- Net revenue 46,647 21,478 ---------
--------- Costs and expenses: Product (1) 11,157 8,891 Research
collaboration 1,120 -- Research and development (1) 4,091 2,409
Selling, general and administrative (1) 45,516 17,120 ---------
--------- Total costs and expenses 61,884 28,420 ---------
--------- Loss from operations (15,237) (6,942) Interest and other
income and expense, net 599 419 --------- --------- Net loss
$(14,638) $(6,523) Net loss per common share: Basic and diluted
$(0.60) $(0.29) ========= ========= Weighted-average number of
shares used in per common share calculations: Basic and diluted
24,304 22,345 ========= ========= (1) Includes the following stock-
based compensation charges: Costs and expenses: Product $332 $173
Research and development 527 319 Selling, general and
administrative 13,934 1,284 --------- --------- $14,793 $1,776
========= ========= DATASOURCE: FoxHollow Technologies, Inc.
CONTACT: Matt Ferguson, Chief Financial Officer, +1-650-421-8501,
or Jonathan Menachem, Investor Relations, +1-650-421-8449, or , or
Robin Gaffney, Media Relations, +1-650-421-8614, or , all of
FoxHollow Technologies, Inc. Web site:
http://www.foxhollowtech.com/
Copyright
Foxhollow (NASDAQ:FOXH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Foxhollow (NASDAQ:FOXH)
Historical Stock Chart
From Jul 2023 to Jul 2024